Delaware General Assembly

Signed 4/28/22

The General Assembly has ended, the current status is the final status.

3/9/22

Heffernan

Sen. Gay, Townsend, S. McBride, Sturgeon
Reps. Longhurst, Minor-Brown, Dorsey Walker

Sen. Hansen, Sokola, Paradee
Reps. Griffith, K. Johnson, Baumbach, Bentz, Kowalko, Morrison, Osienski

AN ACT TO AMEND TITLE 24 RELATING TO PRESCRIBING MEDICATIONS FOR THE TERMINATION OF PREGNANCY.

In 2000, the United States Federal Drug Administration ("FDA") first approved the Risk Evaluation and Mitigation Strategy ("REMS") for Mifeprex; and approved the generic version of Mifeprex, Mifepristone, in 2019. A regimen approved by the FDA in 2016 for Mifeprex and Mifepristone includes the use of Misoprostol. Under the REMS approved by the FDA, healthcare providers who wish to prescribe Mifepristone, Misoprostol, or Mifeprex must complete a Prescriber Agreement before ordering and dispensing the medication. Physicians assistants and advanced practiced registered nurses (APRNs) are healthcare providers who are eligible to prescribe these medications under the REMS. This bill allows physician assistants and advanced practice registered nurses to prescribe medication for the termination of pregnancy including Mifeprex, Mifepristone, and Misoprostol.

83:298

35

4/28/22

N/A

View HTML View PDF